Breaking News

Ziopharm, Regeneron In Clinical Supply Pact

Will evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex with Regeneron’s PD-1 antibody Libtayo in recurrent glioblastoma

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ziopharm Oncology, Inc. has entered a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo (cemiplimab-rwlc) to treat recurrent glioblastoma (rGBM). Ad-RTS-hIL-12 plus veledimex is an investigational gene therapy designed to induce and control the production of human interleukin 12 (hIL-12) that activates the immune system and recruits cancer-fighting T cells into tumors. Libtayo h...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters